Table 2

Changes from baseline of different outcome parameters

Web
(n=90)
FENO
(n=91)
Standard care
(n=87)
Difference web versus standard care
(95% CI)
p ValueDifference FENO versus standard care
(95% CI)
p Value
Asthma-related symptoms
SFD, %
(n=265)
−2.078.90*7.40*−6.60 (−15.5 to 2.3)0.151.17 (−7.6 to 10.0)0.78
ACT or C-ACT
(n=269)
0.121.73*0.370.09 (−0.92 to 1.11)0.861.19 (0.17 to 2.20)0.02*
Daily symptom score
(n=264)
0.08−0.40*−0.110.06 (−0.34 to 0.46)0.77−0.27 (−0.66 to 0.13)0.19
Limitation of activities
(n=258)
0.04−0.09*−0.020.05 (−0.05 to 0.15)0.33−0.05 (−0.15 to 0.05)0.34
Exacerbations
(n=271)
10141770.0730.28†
Medication
SABA use (puffs/day)
(n=270)
−0.15−0.19*−0.18−0.01 (−0.19 to 0.18)0.93−0.12 (−0.30 to 0.07)0.21
ICS dose (μg)
(n=270)
−201*−107*−54−150 (−241 to −60)<0.01**−53 (−144 to 36)0.24
Lung function (z-score)
FEV1
(n=229)
−0.100.16*0.26*−0.22 (−0.46 to 0.02)0.07−0.05 (−0.29 to 0.20)0.71
FVC
(n=229)
−0.040.18*0.22*−0.18 (−0.38 to 0.03)0.09−0.21 (−0.23 to 0.19)0.84
FEF75
(n=221)
−0.200.090.16−0.17 (−0.44 to 0.10)0.210.06 (−0.21 to 0.34)0.65
PD20,DD§
(n=132)
−0.330.14−0.30−0.06 (−1.14 to 1.00)0.920.43 (−0.71 to 1.58)0.46
FENO
(n=266)
1.64‡1.40‡1.18‡1.33 (1.09 to 1.62)<0.01**1.12 (0.92 to 1.38)0.24
Asthma-related quality of life
PAQLQ child
(n=89)
0.170.250.24−0.05 (−0.34 to 0.23)0.72−0.13 (−0.42 to 0.15)0.36
PACQLQ parent0.020.220.050.10 (−0.16 to 0.35)0.440.17 (−0.08 to 0.43)0.17
  • Data shown are mean values of changes as determined by repeated measurements analysis of variance for the diary data, ACT or C-ACT and ICS dose. Analysis of covariance was used for the lung function parameters in the comparison of groups, except for PD20 where the changes are calculated without adjustment for the baseline values.

  • *Significant at *p<0.05, **p<0.025.

  • †Mann–Whitney test.

  • ‡Changes expressed as doubling doses (DD).

  • ¶Changes expressed as ratio of geometric means.

  • ACT, asthma control test; C-ACT, Childhood ACT; ICS, inhaled corticosteroids; PACQLQ, Paediatric Asthma-Related Caregiver Quality of Life Questionnaire; PAQLQ, Paediatric Asthma-Related Quality of Life Questionnaire; SABA, short-acting β agonist; SFD, symptom-free days.